Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Narsoplimab
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (Narsoplimab) is a MASP-2 inhibitor that targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopath...
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 16, 2023
Lead Product(s) : Narsoplimab
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS906 is a humanized mAb which inhibits MASP-3, the key activator of the alternative pathway of complement, it is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and other related indication...
Brand Name : OMS906
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 25, 2023
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OMS527
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $6.6 million
Deal Type : Funding
Details : The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
Brand Name : OMS527
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 10, 2023
Lead Product(s) : OMS527
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $6.6 million
Deal Type : Funding
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $126.0 million
February 06, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : DRI Healthcare Acquisitions
Deal Size : $188.4 million
Deal Type : Agreement
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : DRI Healthcare Acquisitions
Deal Size : $188.4 million
Deal Type : Agreement
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.
Brand Name : OMS906
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 29, 2022
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Narsoplimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 20, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $126.0 million
December 23, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?